+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Healthcare Regulatory Affairs Outsourcing Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941086

Global Healthcare Regulatory Affairs Outsourcing Market Outlook

The global healthcare regulatory affairs outsourcing market size was valued at USD 7.4 billion in 2023, driven by growing trend towards automation in cell dissociation across the world. The market size is anticipated to grow at a CAGR of 9.5% during the forecast period of 2024-2032 to achieve a value of USD 16.7 billion by 2032.

Healthcare Regulatory Affairs Outsourcing: Introduction

Healthcare Regulatory Affairs Outsourcing involves delegating regulatory responsibilities to external organizations specializing in navigating complex legal and regulatory frameworks. This practice is vital for pharmaceutical, biotechnology, and medical device companies seeking to ensure their products comply with global standards. It encompasses tasks like product registration, clinical trial applications, and regulatory submissions. Outsourcing offers expertise, reduces operational costs, and allows companies to focus on core activities while ensuring swift market entry and adherence to stringent healthcare regulations.

Key Trends in the Global Healthcare Regulatory Affairs Outsourcing Market

Companies are increasingly seeking regulatory affairs partners with a global presence and local expertise. This trend is driven by the need to navigate diverse regulatory environments, ensuring compliance with local laws, regulations, and cultural nuances. Outsourcing partners offering multi-regional knowledge are particularly in demand.

There's a growing trend towards specialized outsourcing services. Firms are looking for partners with expertise in specific therapeutic areas or regulatory aspects like clinical trial applications, legal representation, or pharmacovigilance. This specialization ensures that companies receive high-quality advice and can efficiently manage complex regulatory challenges.

Outsourcing firms are increasingly integrating advanced technologies like artificial intelligence (AI) and machine learning (ML) into their services. These technologies help in managing large volumes of regulatory data, predicting trends, and automating routine tasks, thereby increasing efficiency and accuracy.

Companies are not just outsourcing tasks; they are seeking strategic partnerships. These collaborations are long-term and involve close cooperation between the company and the outsourcing firm, ensuring alignment with strategic goals, risk sharing, and continuous improvement in regulatory processes.

There's a shift from transactional relationships to those focusing on strategic value. Companies are looking for outsourcing partners that can offer strategic insights, guiding them through the entire product lifecycle, from development to post-market surveillance, and not just through individual regulatory submissions.

Global Healthcare Regulatory Affairs Outsourcing Market Segmentation

Market Breakup by Services

  • Regulatory Consulting
  • Legal Representation
  • Regulatory Writing and Publishing
  • Product Registration and Clinical Trial Applications

Market Breakup by Categories

  • Drugs
  • Biologics
  • Medical Devices

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Healthcare Regulatory Affairs Outsourcing Market Overview

North America, particularly the United States, leads in healthcare regulatory affairs outsourcing due to its robust pharmaceutical and medical device sectors. The region's stringent FDA regulations necessitate specialized knowledge, making outsourcing a preferred choice for many companies. The presence of numerous biopharmaceutical firms and a strong focus on innovation and research activities further fuel the demand for outsourced regulatory services to navigate the complex approval processes efficiently.

In Europe, the market for healthcare regulatory affairs outsourcing is well-established, driven by the need to comply with diverse regulations like the European Medicines Agency (EMA) standards. Countries such as Germany, the UK, and France are prominent players, with a focus on maintaining high-quality healthcare standards. The evolving regulatory landscape, especially post-Brexit, has increased the complexity and demand for specialized outsourcing services to manage regulatory compliance across different countries.

The Asia-Pacific region is experiencing rapid growth in healthcare regulatory affairs outsourcing, attributed to its expanding pharmaceutical and healthcare sectors. Countries like China, India, and Japan are becoming preferred destinations for outsourcing due to their cost-effectiveness, skilled workforce, and improving regulatory frameworks. The region's market is also driven by increasing foreign investments, a growing focus on healthcare reform, and a surge in drug development activities.

Global Healthcare Regulatory Affairs Outsourcing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Accell Clinical Research
  • Takeda Pharmaceutical Company Limited
  • Genpact
  • Promedica International
  • WuXi AppTec, Inc.
  • PRA Health Sciences
  • Medpace
  • Charles River Laboratories International
  • PAREXEL International Corp.
  • Covance, Inc.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Healthcare Regulatory Affairs Outsourcing Market Overview
3.1 Global Healthcare Regulatory Affairs Outsourcing Market Historical Value (2017-2023)
3.2 Global Healthcare Regulatory Affairs Outsourcing Market Forecast Value (2024-2032)
4 Global Healthcare Regulatory Affairs Outsourcing Market Landscape
4.1 Lentiviral Vectors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Lentiviral Vectors: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Products
4.2.3 Analysis by Applications
5 Global Healthcare Regulatory Affairs Outsourcing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Healthcare Regulatory Affairs Outsourcing Market Segmentation
6.1 Global Healthcare Regulatory Affairs Outsourcing Market by Services
6.1.1 Market Overview
6.1.2 Regulatory Consulting
6.1.3 Legal Representation
6.1.4 Regulatory Writing and Publishing
6.1.5 Product Registration and Clinical Trial Applications
6.2 Global Healthcare Regulatory Affairs Outsourcing Market by Categories
6.2.1 Market Overview
6.2.2 Drugs
6.2.3 Biologics
6.2.4 Medical Devices
6.3 Global Healthcare Regulatory Affairs Outsourcing Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Healthcare Regulatory Affairs Outsourcing Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Healthcare Regulatory Affairs Outsourcing Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Healthcare Regulatory Affairs Outsourcing Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Healthcare Regulatory Affairs Outsourcing Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Healthcare Regulatory Affairs Outsourcing Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Accell Clinical Research
14.1.1 Financial Analysis
14.1.2 Product Portfolio
14.1.3 Demographic Reach and Achievements
14.1.4 Mergers and Acquisitions
14.1.5 Certifications
14.2 Takeda Pharmaceutical Company Limited
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 Genpact
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Promedica International
14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 WuXi AppTec, Inc.
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 PRA Health Sciences
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 Medpace
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 Charles River Laboratories International
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 PAREXEL International Corp.
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Covance, Inc.
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic Reach and Achievements
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Accell Clinical Research
  • Takeda Pharmaceutical Company Limited
  • Genpact
  • Promedica International
  • WuXi AppTec Inc.
  • PRA Health Sciences
  • Medpace
  • Charles River Laboratories International
  • PAREXEL International Corp.
  • Covance Inc.

Methodology

Loading
LOADING...

Table Information